Oyster Point is now a part of Viatris - click here

This site is intended for US audiences only

Oyster Point Pharma Terms of Use

Last Updated: June 2021

Website Terms of Use

These Terms of Use govern the use of the Oyster Point Pharma, Inc. website. ANYONE ACCESSING THE SITE AGREES TO ABIDE BY THESE TERMS. Oyster Point Pharma, Inc. (“Oyster Point Pharma”, “we”, our or “us”) may modify these Terms of Use at any time, and such modification shall be effective immediately upon posting on the website. Your continued access or use of the website after the modifications have become effective shall be deemed your conclusive acceptance of the modified Terms of Use.

Ownership
All content of this Internet site is owned or controlled by Oyster Point Pharma and is protected by worldwide copyright laws. You may download content only for your personal use for non-commercial purposes, but no modification or further reproduction of the content is permitted, and you must retain on such content all copyright and other proprietary notices applicable to the content. The content may otherwise not be copied or used in any way.

Any trademarks, service marks, trade names, trade dress, products or other intellectual property rights in this website are protected in the United States and internationally. No use of any of these may be made without the prior, written authorization of Oyster Point Pharma, except to identify the products or services of Oyster Point Pharma.

Except as required by our Privacy Policy, the owners of this website shall be free to use or copy any information included in any communications to this website, including any ideas, inventions, concepts, techniques or know-how disclosed to us, for any purposes. Such purposes may include disclosure to third parties and developing, manufacturing and marketing goods or services.

Links
This website may contain links to websites maintained by other companies. Oyster Point Pharma provides any such links to you only as a convenience. The inclusion of any link does not imply that Oyster Point Pharma endorses any third-party Website or third-party company or product. Oyster Point Pharma does not have any control over the content of such third-party websites and assumes no responsibility whatsoever for the accuracy of any information presented at such other websites, or for their functionality. Oyster Point Pharma also shall not be liable for any damage to, or viruses that may infect, your computer equipment or other property on account of your access to, or use of such other websites.

Products
The safety and efficacy of the product candidates and uses under investigation have not been established. There is no guarantee that any of the product candidates will receive health authority approval or become commercially available in any country for any of the uses being investigated.

This website may contain information on products and services that are not available or approved by the appropriate regulatory authorities in your country. Such references do not imply that such products or services are or will be available in your location. The products and services referred to on this website may be subject to different regulatory requirements depending on the country of use. Nothing on this website should be considered to be a promotion or advertisement for any product or service in country or for the use of any product or service that is not authorized by the laws and regulations of your country of residence.

Warranties, Limitations of Liability
Oyster Point Pharma will use reasonable efforts to include up-to-date and accurate information in this website, but we make no representations, warranties, or assurances as to the accuracy, currency, or completeness of the information provided. OYSTER POINT PHARMA SHALL NOT BE LIABLE FOR ANY DIRECT, INCIDENTAL, CONSEQUENTIAL, INDIRECT OR PUNITIVE DAMAGES ARISING OUT OF ACCESS TO, USE OF OR INABILITY TO USE THIS SITE, OR ANY ERRORS OR OMISSIONS IN THE CONTENT OF THE WEBSITE. OYSTER POINT PHARMA ALSO SHALL NOT BE LIABLE FOR ANY DAMAGE TO, OR VIRUSES THAT MAY INFECT, YOUR COMPUTER EQUIPMENT OR OTHER PROPERTY ON ACCOUNT OF YOUR ACCESS TO, OR USE OF THE WEBSITE.

Disclosure Regarding Forward-Looking Statements
The information contained in this website includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current beliefs, expectations and assumptions of the “Company regarding the future of the Company’s business, our future plans and strategies, regulatory approvals, clinical results, future financial condition and other future conditions.

All statements other than statements of historical facts contained in this press release, including express or implied statements regarding future results of operations and financial position, business strategy, product candidates, regulatory approvals, expected research and development costs, planned preclinical studies and clinical trials, expected results of clinical trials, and their timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. The words “if approved,” “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things: the timing or likelihood of regulatory filings and approvals for our product candidates; our ability to obtain and maintain regulatory approvals of our product candidates; our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; our plans relating to the further development and manufacturing of our product candidates, including additional indications or disease areas to be evaluated and pursued; the impact of the COVID-19 pandemic on our business, operations, and regulatory and clinical development timelines, plans and expectations; the prevalence of dry eye disease and Neurotrophic Keratopathy (NK) and the size of the market opportunities for our product candidates; the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates, and other positive results; the timing of initiation of our future clinical trials, and the reporting of data from our current and future trials; the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise; existing regulations and regulatory developments in the United States and other jurisdictions; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available; our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials, and potentially for commercial supply; our ability to recruit and retain key personnel needed to develop and commercialize our product candidates, if approved, and to grow our company; the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; our financial performance; market conditions; the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements; our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and other risks described in the “Risk Factors” section included in our public filings that we have made and will make with the Securities and Exchange Commission (SEC).

The information in this website speaks only as of the date the information was published. Oyster Point Pharma assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this website as current or accurate after its publication date.